Revah joins Genethon as ceo
Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.
Revah brings more than 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.
Immediately prior to joining Genethon, Revah had been chief executive of the oncology start-up Sepal Pharma since 2008. Before that, he was vice president, Drug Discovery, and chief scientific officer of Cerep from 1999 to 2007 and chief executive of its oncology subsidiary.
You may also like
Research & Development
![Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal]()
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Design & Build
![Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy]()
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy
The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours